Use of semaglutide and risk of non‐arteritic anterior ischemic optic neuropathy: A Danish–Norwegian cohort study
The use of semaglutide for managing type 2 diabetes is associated with an increased risk of NAION compared with the use of SGLT-2is. However, the absolute risk remains low.
Authors
- Øystein Kalsnes Jørstad (ORCID: https://orcid.org/0000-0003-1259-0653)
- László Hegedüs (ORCID: https://orcid.org/0000-0002-9691-7619)
- Lars Christian Lund (ORCID: https://orcid.org/0000-0001-8651-6072)
- Martin Ernst (ORCID: https://orcid.org/0000-0001-9003-3823)
- Hanne Løvdal Gulseth (ORCID: https://orcid.org/0000-0001-5057-4449)
- Emma Simonsen (ORCID: https://orcid.org/0000-0002-0254-0479)
- Anton Pottegård (ORCID: https://orcid.org/0000-0001-9314-5679)
- Vidar Hjellvik (ORCID: https://orcid.org/0000-0002-2379-9906)
- Steffen Hamann (ORCID: https://orcid.org/0000-0003-4318-2716)
- Øystein Karlstad (ORCID: https://orcid.org/0000-0003-1204-787X)
Institutions
- University of Copenhagen (DK)
- Oslo University Hospital (NO)
- Norwegian Institute of Public Health (NO)
- University of Southern Denmark (DK)
- University of Oslo (NO)
- Odense University Hospital (DK)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-03-17
- DOI
- https://doi.org/10.1111/dom.16316
- Citations
- 31
- Primary Topic
- Intraoperative Neuromonitoring and Anesthetic Effects
- Type
- article
- Field-Weighted Citation Impact
- 62.20
Funders
- Danmarks Frie Forskningsfond